双次自体造血干细胞移植治疗T淋巴母细胞淋巴瘤21例的临床疗效观察
发布时间：2018-07-24 11:51
【摘要】：目的探讨双次自体造血干细胞移植(autologous peripheral blood stem cell transplant,APSCT)治疗T淋巴母细胞淋巴瘤的临床疗效和安全性。方法收集2008年2月至2013年11月在我院血液病中心接受双次APSCT的T淋巴母细胞淋巴瘤患者共21例,中位年龄29岁。按照Ann Arbor标准,Ⅲ期5例,Ⅳ期16例,第1次移植前处于完全缓解(complete remission,CR)16例,部分缓解(partial remission,PR)为5例。第1次移植采用以环己亚硝脲+依托泊苷+阿糖胞苷+环磷酰胺联合方案进行预处理,以上患者在第1次移植后4~6个月进行第2次造血干细胞移植,预处理方案为伊达比星+阿糖胞苷+环磷酰胺。结果 1所有患者双次自体移植后造血功能均顺利重建。2中位随访24个月,复发3例,死亡4例(因复发死亡2例,疾病进展死亡1例,移植相关死亡1例),无病存活12例,4例疾病稳定,1例研究截止时疾病复发进展。3年预期无进展生存为68.9%,总生存率为73.6%。3预后相关因素中,患者的年龄、第1次移植后疾病状态是否CR影响患者的总生存期(overall survival,OS)和无进展生存期(progression-free survival,PFS),第1次移植前疾病状态是否CR影响患者的OS。结论双次APSCT治疗T淋巴母细胞淋巴瘤患者疗效确切,造血重建顺利,移植相关死亡率低,安全性好。
[Abstract]:Objective to investigate the clinical efficacy and safety of double autologous hematopoietic stem cell transplantation (autologous peripheral blood stem cell transplant- APSCT) in the treatment of T lymphoblastic lymphoma. Methods from February 2008 to November 2013, 21 patients with T lymphoblastic lymphoma who received double APSCT from February 2008 to November 2013 were collected. The median age was 29 years. According to Ann Arbor criteria, there were 5 cases in stage 鈪，
本文编号：2141289
[Abstract]:Objective to investigate the clinical efficacy and safety of double autologous hematopoietic stem cell transplantation (autologous peripheral blood stem cell transplant- APSCT) in the treatment of T lymphoblastic lymphoma. Methods from February 2008 to November 2013, 21 patients with T lymphoblastic lymphoma who received double APSCT from February 2008 to November 2013 were collected. The median age was 29 years. According to Ann Arbor criteria, there were 5 cases in stage 鈪，
本文编号：2141289
本文链接：https://www.wllwen.com/huliyixuelunwen/2141289.html
最近更新
教材专著
